GlassScriptPhysician profile
David Surprenant
NPI 1265895932
$5,251.73
in general payments reported to CMS, 2019-2025
22 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 82% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2021: $500 · 2022: $882 · 2023: $1,108 · 2024: $1,211 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,771.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,041.34 | 2021-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $513.95 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $453.36 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $439.33 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $414.96 | 2021-2025 | Tremfya |
| Genzyme Corporation | $336.19 | 2021-2024 | |
| Amgen INC. | $303.76 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $255.63 | 2021-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $233.66 | 2023-2025 | Affinity, Puraply |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $193.31 | 2021-2025 | Cabtreo, Jublia |
| Galderma Laboratories, L.P. | $171.77 | 2024-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $167.59 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Incyte Corporation | $152.91 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $150.85 | 2023-2025 | Zoryve |
| Ucb, INC. | $116.65 | 2024-2025 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.41 | 2023-2025 | Spevigo |
| Allergan, INC. | $97.33 | 2019 | |
| Organon LLC | $49.88 | 2023-2025 | Hadlima |
| Biofrontera INC. | $17.54 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $16.50 | 2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $14.10 | 2024 | Ycanth |
| Genentech USA, INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Surprenant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.